Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 28;12(4):812.
doi: 10.3390/cancers12040812.

Personalized Medicine-Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer

Christine Koulis  1 , Raymond Yap  1 , Rebekah Engel  1   2   3 , Thierry Jardé  2   3   4 , Simon Wilkins  1   5 , Gemma Solon  1 , Jeremy D Shapiro  6 , Helen Abud  2   3 , Paul McMurrick  1
Affiliations
Review

Personalized Medicine-Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer

Christine Koulis et al. Cancers (Basel). .

Abstract

Colorectal cancer (CRC) is the third most common cancer diagnosed worldwide and is heterogeneous both morphologically and molecularly. In an era of personalized medicine, the greatest challenge is to predict individual response to therapy and distinguish patients likely to be cured with surgical resection of tumors and systemic therapy from those resistant or non-responsive to treatment. Patients would avoid futile treatments, including clinical trial regimes and ultimately this would prevent under- and over-treatment and reduce unnecessary adverse side effects. In this review, the potential of specific biomarkers will be explored to address two key questions-1) Can the prognosis of patients that will fare well or poorly be determined beyond currently recognized prognostic indicators? and 2) Can an individual patient's response to therapy be predicted and those who will most likely benefit from treatment/s be identified? Identifying and validating key prognostic and predictive biomarkers and an understanding of the underlying mechanisms of drug resistance and toxicity in CRC are important steps in order to personalize treatment. This review addresses recent data on biological prognostic and predictive biomarkers in CRC. In addition, patient cohorts most likely to benefit from currently available systemic treatments and/or targeted therapies are discussed in this review.

Keywords: biomarkers; colorectal cancer; consensus molecular subtypes; organoid; predictive; prognostic.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Haggar F.A., Boushey R.P. Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. Clin. Colon Rectal Surg. 2009;22:191–197. doi: 10.1055/s-0029-1242458. - DOI - PMC - PubMed
    1. Hong S.N. Genetic and epigenetic alterations of colorectal cancer. Intest. Res. 2018;16:327–337. doi: 10.5217/ir.2018.16.3.327. - DOI - PMC - PubMed
    1. Poulogiannis G., Frayling I.M., Arends M.J. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. Histopathology. 2010;56:167–179. doi: 10.1111/j.1365-2559.2009.03392.x. - DOI - PubMed
    1. Sargent D.J., Marsoni S., Monges G., Thibodeau S.N., Labianca R., Hamilton S.R., French A.J., Kabat B., Foster N.R., Torri V., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol. 2010;28:3219–3226. doi: 10.1200/JCO.2009.27.1825. - DOI - PMC - PubMed
    1. Grant M., Haydon A., Au L., Wilkins S., Oliva K., Segelov E., Antill Y., Carne P., Ranchod P., Polglase A., et al. Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: A cohort study of two cancer centres. Int. J. Surg. 2018;51:71–75. doi: 10.1016/j.ijsu.2018.01.020. - DOI - PubMed

LinkOut - more resources